Adlai Nortye Ltd. (ANL)
| Market Cap | 251.45M |
| Revenue (ttm) | 5.00M |
| Net Income (ttm) | -104.87M |
| Shares Out | 16.99M |
| EPS (ttm) | -7.26 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,552 |
| Open | 13.52 |
| Previous Close | 13.75 |
| Day's Range | 13.52 - 14.90 |
| 52-Week Range | 7.11 - 19.30 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 30.00 (+102.7%) |
| Earnings Date | May 13, 2024 |
About ANL
Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recur... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for ANL stock is "Buy" and the 12-month stock price forecast is $30.0.
News
Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, March 29, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company fo...
Adlai Nortye Announces Completion of Patient Enrollment in Global Phase III Clinical Trial of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company foc...
Adlai Nortye Ltd. & Nucleai awarded ESMO 2023 BEST Poster Award
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a global clinical-stage biotechnology comp...
Adlai Nortye Ltd. Announces Closing of Initial Public Offering
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company foc...
Adlai Nortye Ltd. Announces Pricing of Initial Public Offering
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company fo...
Cancer treatment company Adlai Nortye sets terms in IPO
Adlai Nortye Ltd. said late Thursday it plans to offer three million American depositary shares at an estimated price of $22 to $26 a share in its initial public offering on the Nasdaq under the symbo...